Related Image: American Chemical Society's Weekly PressPac -- Oct. 31, 2007 |
(Date:12/1/2009)...CRANBURY, N.J., Dec. 1 P... announced that the U.S. Patent and Trademark Offi...yclic Natriuretic Peptide Constructs." The claims...pounds that bind to natriuretic peptide receptor A...ailure drug candidate. ,, "Our natriuretic comp...
(Date:12/1/2009)... , HARBIN, China, Dec. 1 /PRNewswire-Asia... Sky One Medical" or "the Company") (Nasdaq: CSKI...any developing and producing,over-the-counter drug...,announced that the Company has engaged Guangdong ...any ("MDK") to serve as its exclusive sales agent ...
(Date:12/1/2009)... DNA Genotek, a leading provider of p...nounced that Tepnel Pharmaceutical Services will o...rt of its nucleic acid extraction and genotyping s...EB) December 1, 2009 -- DNA Genotek , a leading p...on, today announced that Tepnel Pharmaceutical Se...
(Date:12/1/2009)... California waste-to-energy firm clai...bon sequesteration, smallest footprint, salable pu... , (PRWEB) December 15, 2... new innovative organic waste-to-energy process wi...nce in January. , , ,This biowaste process known...
Breaking Biology Technology:Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 2Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 3China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia 2China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia 3Tepnel Pharmaceutical Services to Offer DNA Genotek's Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service 2Tepnel Pharmaceutical Services to Offer DNA Genotek's Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service 3First Public Showing of Innovative Waste-to-Energy Process 2...oration (Nasdaq: NEOG ) announces the following ...r Results Webcast , , When: Thursday, March 19, ...onewswire.com/event.asp?id=56632 , , How: Live ...he address above. , , Contact: Terry Maynard o... are unable to participate during the live webcast...
...d on its recent analysis of the radio-frequency id...ems market, Frost & Sullivan recognizes Covidi...an Product Innovation Award for developing a contr...,s contrast delivery system combines its unit-dose...ia syringes with its RFID enabled Optivantage(TM) ...
...1, 2009 at 4:30 p.m. Eastern Time , , BOTHELL, WA... OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or t...ts fourth quarter and fiscal year 2008 financial r...ided an outlook for 2009. , "2008 was a tremendous...took measures to prepare for the final stages of c...
Other Biology Technology:Frost & Sullivan Recognizes Covidien for Its CT Contrast Delivery System With RFID Enabled Intelligence 2Frost & Sullivan Recognizes Covidien for Its CT Contrast Delivery System With RFID Enabled Intelligence 3Frost & Sullivan Recognizes Covidien for Its CT Contrast Delivery System With RFID Enabled Intelligence 4OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 2OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 3OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 4OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 5OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 6OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 7OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 8OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 9OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 10OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 11OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 12Rabbit Anti-NEOPTERIN Polyclonal Antibody, Unconjugated from AbD Serotec
Beagle Serum from Innovative Research
Normal Donor Donkey Serum from Equitech-Bio
X-Gal/IPTG Solution from Bioline
Biology Products: